论文部分内容阅读
目的探讨低分子肝素钙、依达拉奉联合治疗进展型脑梗死的临床疗效。方法将河北省唐山市丰润区人民医院神经内科2009-02-2010-07进展型脑梗死患者92例随机分为观察组和对照组,每组各46例,两组均在常规治疗基础上,观察组应用低分子肝素钙和依达拉奉,对照组应用依达拉奉,进行神经功能缺损评分并评价临床疗效。结果观察组患者的神经功能缺损改善情况明显优于对照组(P<0.01)。结论低分子肝素钙与依达拉奉联用治疗进展型脑梗死,可更有效终止病情进展,改善神经功能缺损,提高临床疗效。
Objective To investigate the clinical efficacy of low molecular weight heparin and edaravone in the treatment of advanced cerebral infarction. Methods 92 cases of patients with progressive cerebral infarction were randomly divided into observation group and control group, 46 cases in each group.On the basis of routine treatment, Low-molecular-weight heparin and edaravone were used in the observation group. Edaravone was used in the control group to evaluate neurological deficit and evaluate the clinical efficacy. Results The improvement of neurological deficits in observation group was significantly better than that in control group (P <0.01). Conclusions The combination of low molecular weight heparin and edaravone in treatment of advanced cerebral infarction can effectively stop the progression of the disease, improve neurological deficits and improve clinical efficacy.